Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 1:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 369 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Locally Advanced Head and Neck Cancer Clear all
Completed Phase 3 Interventional Results available

Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer

NCT00655876
View directory record Official record
Conditions
Esophageal Cancer
Interventions
cetuximab, cisplatin, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 74 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2022
U.S. locations
173
States / cities
Tucson, Arizona • Auburn, California • Cameron Park, California + 140 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 4, 2026, 1:03 PM EDT
Recruiting Phase 1Phase 2 Interventional

Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer

NCT05156060
View directory record Official record
Conditions
Head and Neck Cancer, Locally Advanced Head and Neck Carcinoma
Interventions
Gabapentin, Ketamine
Drug
Lead sponsor
Natalie Lockney
Other
Eligibility
21 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 4, 2026, 1:03 PM EDT
Not yet recruiting Early Phase 1 Interventional

[18F]-AraG PET Imaging in LA HNSCC

NCT07168785
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC), Locally Advanced Head and Neck Squamous Cell Carcinoma
Interventions
[18F]-AraG radiotracer, Chemotherapy, Radiotherapy
Drug · Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 4, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer

NCT00134043
View directory record Official record
Conditions
Insular Thyroid Cancer, Recurrent Thyroid Cancer, Stage II Follicular Thyroid Cancer, Stage II Papillary Thyroid Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Papillary Thyroid Cancer, Thyroid Gland Medullary Carcinoma
Interventions
vorinostat
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 11, 2014 · Synced Oct 4, 2026, 1:03 PM EDT
Recruiting Phase 2 Interventional

Window of Opportunity in Preserving Laryngeal Function Trial

NCT07423078
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Locally Advanced Laryngeal Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma
Interventions
Toripalimab, Carboplatin, Cisplatin, Paclitaxel, Radiation Therapy
Drug · Radiation
Lead sponsor
Matthew Spector
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 4, 2026, 1:03 PM EDT
Active, not recruiting Phase 1 Interventional

Cryotherapy for Locally Advanced Esophageal Cancer

NCT04248582
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Cryotherapy
Device
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 4, 2026, 1:03 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

NCT04032704
View directory record Official record
Conditions
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma
Interventions
ladiratuzumab vedotin, pembrolizumab
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
27
States / cities
Chandler, Arizona • Los Angeles, California • Santa Rosa, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 4, 2026, 1:03 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

NCT05070247
View directory record Official record
Conditions
Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer, Gastric Cancer, Esophageal Cancer, Nasopharyngeal Cancer, Kidney Cancer, Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Non-squamous
Interventions
TAK-500, Pembrolizumab, Tocilizumab, Dexamethasone
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
12
States / cities
Birmingham, Alabama • Duarte, California • La Jolla, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 4, 2026, 1:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma

NCT02759575
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Pembrolizumab, Radiation Therapy, Cisplatin
Drug · Radiation
Lead sponsor
Vinita Takiar
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 12, 2021 · Synced Oct 4, 2026, 1:03 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)

NCT07405151
View directory record Official record
Conditions
Oesophageal Squamous Cell Carcinoma
Interventions
I-DXd, Rescue Medication
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 4, 2026, 1:03 PM EDT
Terminated Early Phase 1 Interventional

Ferumoxytol - Iron Oxide Nanoparticle Magnetic Resonance Dynamic Contrast Enhanced MRI

NCT01895829
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Magnetic Resonance Imaging (MRI), Ferumoxytol
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Oct 4, 2026, 1:03 PM EDT
Completed Phase 1 Interventional

Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors

NCT00010023
View directory record Official record
Conditions
Cancer
Interventions
capecitabine, cisplatin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2011 · Synced Oct 4, 2026, 1:03 PM EDT
Completed Early Phase 1 Interventional

Pilot Trial of Microsphere Oxycodone (Xtampza ER) for Pain Management in Patients Receiving Radiotherapy for Locally Advanced Head and Neck Cancer

NCT03317730
View directory record Official record
Conditions
Locally Advanced Head and Neck Cancer
Interventions
Xtampza ER
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Oct 4, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer

NCT00217581
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Bevacizumab, Docetaxel, Oxaliplatin
Biological · Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
4
States / cities
Ann Arbor, Michigan • Detroit, Michigan • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 4, 2026, 1:03 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors

NCT04305795
View directory record Official record
Conditions
Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma
Interventions
200 mg Pembrolizumab, 350 mg Cemiplimab, ASP-1929 PIT
Biological · Combination Product
Lead sponsor
Rakuten Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Miami, Florida • Lexington, Kentucky • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2025 · Synced Oct 4, 2026, 1:03 PM EDT
Completed Phase 1 Interventional

sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC

NCT04091867
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
sEphB4-HSA with chemotherapy, Cetuximab, Radiation Therapy
Drug · Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 4, 2026, 1:03 PM EDT
Terminated Phase 1 Interventional Results available

A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC

NCT00882583
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Cetuximab, Dasatinib, Cisplatin, Radiation Therapy
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 4, 2026, 1:03 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

NCT05581004
View directory record Official record
Conditions
Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma, TNBC, Esophageal Cancer, Gastric Cancer, Cervical Cancer, Colorectal Cancer, Urothelial Carcinoma, Clear Cell RCC, HCC
Interventions
Enzelkitug, Atezolizumab, Pembrolizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
10
States / cities
San Francisco, California • Aurora, Colorado • Sarasota, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 4, 2026, 1:03 PM EDT
Recruiting Phase 3 Interventional

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

NCT06256588
View directory record Official record
Conditions
Neoplasms, Head and Neck
Interventions
Dostarlimab, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
36
States / cities
Jonesboro, Arkansas • Los Angeles, California • Solvang, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 4, 2026, 1:03 PM EDT
Completed Not applicable Interventional Results available

Navigation vs Usual Care for Timely Adjuvant Therapy for Patients With Locally Advanced HNSCC

NCT04030130
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
NDURE
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 4, 2026, 1:03 PM EDT
Completed Phase 1 Interventional

Soy Isoflavone in Combination With Radiation Therapy and Cisplatin in SCC of the Head and Neck

NCT02075112
View directory record Official record
Conditions
Cancer of Head and Neck
Interventions
Soy isoflavone, Radiation, Cisplatin
Drug · Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 6, 2019 · Synced Oct 4, 2026, 1:03 PM EDT
Active, not recruiting Phase 2 Interventional

Soylent in Reducing Gastrostomy Tube Rates in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemoradiotherapy

NCT07242365
View directory record Official record
Conditions
Locally Advanced Head and Neck Carcinoma
Interventions
Soylent Graham Dietary Supplement, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration
Dietary Supplement · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 4, 2026, 1:03 PM EDT
Recruiting Phase 2 Interventional

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT06172478
View directory record Official record
Conditions
Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer, Non-small Cell Lung Cancer (NSCLC), Lung Cancer, Breast Cancer
Interventions
HER3-DXd
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
13
States / cities
Duarte, California • New Haven, Connecticut • Kissimmee, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 4, 2026, 1:03 PM EDT
Completed Phase 1 Interventional

C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck

NCT00402545
View directory record Official record
Conditions
Head and Neck Neoplasms
Interventions
Cetuximab, Docetaxel, Cisplatin, 5-Fluorouracil
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2009 · Synced Oct 4, 2026, 1:03 PM EDT